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ABSTRACT 1 
 2 
Background: 3 
Asymptomatic Atrial fibrillation (AF) is increasingly common in the ageing population 4 
and implicated in many ischaemic strokes. Earlier identification of AF with appropriate 5 
anticoagulation may decrease stroke morbidity and mortality.  6 
 7 
Methods: 8 
We conducted a randomized controlled trial (DOI 10.1186/ISRCTN10709813) of AF 9 
screening using an AliveCor Kardia monitor attached to a Wifi enabled iPod to obtain 10 
electrocardiograms (iECG) in ambulatory patients. Patients ≥65y with CHADS-VASc ≥2 11 
free from AF were randomized to iECG arm or routine care (RC). iECG participants 12 
acquired iECGs twice-weekly over 12-months (+ additional iECGs if symptomatic) onto 13 
a secure study server with over-read by an automated AF detection algorithm and also 14 
by cardiac physiologist +/- consultant cardiologist. Time to diagnosis of AF was the 15 
primary outcome measure. The overall cost of the devices, ECG interpretation and 16 
patient management was captured and utilized to generate the cost per AF diagnosis in 17 
iECG patients. Clinical events and patient attitudes/experience were also evaluated. 18 
 19 
Results: 20 
We studied 1001 patients (500 iECG, 501 RC) aged 72.6+/-5.4y, 534 female. Mean 21 
CHADS-VASc score was 3.0 (heart failure = 1.4%; hypertension = 54%; diabetes mellitus 22 
= 30%; prior stroke/TIA = 6.5%; arterial disease = 15.9%. All CHADS-VASc risk factors 23 
were evenly distributed between groups). 24 
 25 
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Nineteen patients in the iECG group were diagnosed with AF over the 12 month study 1 
period vs 5 in the RC arm (Hazard Ratio 3.9, 95%CI = 1.4-10.4, p = 0.007) at a cost per 2 
AF diagnosis of $10,780 (£8,255). There were a similar number of stroke/TIA/systemic 3 
embolic events (6 vs 10 iECG vs RC HR=0.61, 95%CI = 0.22-1.69, p=0.34) 4 
The majority of iECG patients were satisfied with the device, finding it easy to use, 5 
without restricting activities or causing anxiety.  6 
 7 
Conclusions: 8 
Screening using twice-weekly single lead iECG with remote interpretation in 9 
ambulatory patients ≥65y at increased risk of stroke is significantly more likely to 10 
identify incident AF than RC over a 12-month period. This approach is also highly 11 
acceptable to this group of patients, supporting further evaluation in an appropriately-12 
powered, event-driven clinical trial. 13 
 14 
Clinical Trial Registration:  15 
ISRCTN10709813 DOI 10.1186/ISRCTN10709813 16 
 17 
https://www.isrctn.com/ISRCTN10709813?q=Assessment%20of%20REmote%20HEArt18 
%20Rhythm%20Sampling%20using%20the%20AliveCor%20heart%20monitor%20to%219 
0scrEen%20for%20Atrial%20Fibrillation&filters=&sort=&offset=1&totalResults=1&page=20 
1&pageSize=10&searchType=basic-search 21 
  22 
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Clinical Perspective 1 
 2 
What is new? 3 
 This is the first prospective randomized trial evaluating the ability of remote ECG 4 
acquisition and transmission using a handheld device with remote interpretation 5 
to screen for atrial fibrillation (AF) in at risk people over 65y over an extended 6 
period of time (1y). 7 
  This approach is at least 3 times more likely to identify incident AF than routine 8 
care at a cost of just over $10,000 per case identified and is a highly acceptable 9 
approach in this group of patients. A CHADS-VASc score of ≥4 was the strongest 10 
predictor of incident AF. 11 
 12 
What are the clinical implications? 13 
 Our findings suggest that this approach could be considered for AF screening in 14 
routine practice, particularly in the highest risk patients.  15 
 Although strokes and TIAs were numerically fewer in monitored patients, the 16 
study was not statistically powered to evaluate hard clinical outcomes and this 17 
difference was not statistically significant.  18 
 These results support consideration of evaluation in an appropriately-powered, 19 
event-driven randomised trial to confirm clinical and cost-effectiveness of such 20 
an approach to stroke prevention in AF. 21 
  22 
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INTRODUCTION 1 
 2 
Atrial fibrillation (AF) is a common cardiac arrhythmia, affecting an estimated 33.5 3 
million individuals worldwide.1 AF is an important risk factor for stroke, being 4 
implicated in up to 1 in 3 cases2-4 and often not diagnosed beforehand.5 AF-related 5 
strokes commonly result in greater disability than ischemic stroke secondary to arterial 6 
disease.6  7 
 8 
The annual stroke risk conferred by AF increases with age and other common risk 9 
factors and can be estimated using the CHADS-VASc score in those without rheumatic 10 
mitral valve disease or metallic valvular prosthesis.7 Stroke risk can be reduced by 11 
around two thirds by the use of oral anticoagulant (OAC) therapy (including 12 
nonvitamin-K antagonists (N)OACs). 8,9 13 
 14 
Presentation with AF may be atypical or asymptomatic, especially in older subjects.10  15 
Data from a range of sources (including the retrospective MOST study and the TRENDS 16 
study), have shown that asymptomatic AF may potentially pose a greater 17 
thromboembolic risk than where symptoms are typical.10-14 AF may also occur on an 18 
intermittent basis (“paroxysmal” [PAF]), with an increased stroke risk15, 16 and identical 19 
recommendations for antithrombotic management as permanent AF.  20 
 21 
AF incidence varies according to the population characteristics and diagnostic 22 
strategy.17 Single-timepoint ECG recording in a general population ≥65 years of age 23 
identified AF in 1.4%.18 Furthermore, twice-daily intermittent single lead ECG recording 24 
over two weeks using a handheld device identified AF in 3.0% of 75-76 year olds, 25 
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including 7.4% of those screened who had ≥1 additional stroke risk factor.19, 20  A recent 1 
expert consensus paper has confirmed that AF identified at screening is not benign and 2 
justifies consideration of anticoagulation in those with stroke risk factors.21 Whilst 3 
validated handheld electrocardiogram (ECG) recording devices are already considered 4 
appropriate technologies for AF screening, expert groups recognize that large 5 
prospective trials are required to strengthen the evidence base and refine population 6 
screening strategies.21  7 
 8 
We therefore undertook a 1-year randomized controlled trial of twice weekly 9 
monitoring with the AliveCor Kardia device (a smartphone/tablet-based single lead ECG 10 
capture system) versus routine clinical care in patients over the age of 65 with ≥1 11 
additional stroke risk factor.22 The Primary outcome was incidence and time to 12 
diagnosis of AF. 13 
 14 
METHODS (Full methods: Supplement 1) 15 
Study Population 16 
Individuals over 65y with a CHADS-VASc score ≥2 without a known diagnosis of AF, 17 
currently in receipt of OAC therapy, a known contraindication to anticoagulation or 18 
permanent cardiac pacing implant were recruited. Participants were required to have 19 
access to the internet via Wifi and be able to operate the AliveCor Kardia system 20 
(AliveCor inc. Mountain View, CA) attached to an iPod (Apple inc. Cupertino CA) after 21 
simple instruction. Eligibility was confirmed by a brief history, physical examination 22 
and single lead ECG recorded with the AliveCor device (iECG). Written consent was 23 
obtained and eligible participants were randomised (1:1) to an “intervention” (iECG) 24 
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group or routine care (RC) group. Ethical approval was obtained from the Wales 1 
Research Ethics Committee 6 (REC Reference 14/WA/1227).  2 
 3 
Participants in the “intervention” iECG arm were instructed to undertake twice weekly 4 
recording and transmission of a 30 second single lead iECG trace to a secure server 5 
(Monday and Wednesday recommended, plus additional submissions if symptomatic), 6 
over a 12 month period. iECG traces were analyzed by an automated analysis software 7 
algorithm (AliveCor version 2.2.0 [build 21]) and also sent for offline analysis by a 8 
physiologist-led ECG reading service (Technomed Ltd UK). Abnormal ECGs were over 9 
read by a cardiologist with clinical review and appropriate care arranged for those with 10 
AF or other clinically significant arrhythmia. Patients in the RC arm were followed up as 11 
normal by their general practitioner. All patients were contacted by a member of the 12 
study team at 12, 32 and 52 weeks to assess progress. Clinical events were followed up 13 
and confirmed by clinical chart review. 14 
 15 
Patients with Identified AF 16 
AF was defined as a 30-second iECG recording with irregular rhythm without p waves.23  17 
All new AF diagnoses were confirmed and reviewed by a senior study cardiologist who 18 
made arrangements for OAC initiation and clinical management according to current UK 19 
(NICE) guidance.24  RC participants with AF were diagnosed and managed by local 20 
clinicians, with all AF diagnoses validated by a study cardiologist. 21 
 22 
Clinical Event Monitoring 23 
Adverse events (AEs) were reported either at the time of event or identified by 24 
telephone at 12, 32 and 52 weeks, with confirmation from source clinical records.  25 
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 1 
Participant Experience Survey 2 
All study participants were invited to participate in a survey at the end of the study. 3 
They were asked if they were more anxious about and more aware of heart rhythm 4 
problems, whether they were more likely to visit their doctor or if they would prefer to 5 
switch study group (Responses reported via 10-point visual analog scale). iECG patients 6 
were also asked about ease of use, restriction of activities, anxiety, concern regarding 7 
data security and their general satisfaction with the device (Responses reported via 5-8 
point Likert scale).  9 
 10 
Health Economic Evaluation  11 
The costs associated with screening for AF using AliveCor device were estimated from 12 
the perspective of the UK NHS and personal social services,25 utilising data from study 13 
activity and relevant costs.26-28   14 
 15 
Statistical Methods 16 
The study sample size of 500 participants per study arm was estimated to provide 92% 17 
power to detect a significant difference (α=5%) in the time to AF diagnosis between 18 
groups (PS: Power and Sample Size Calculation version 3.1.2, 2014).29  19 
Baseline characteristics were compared using either a Chi-square test (for groups), 20 
Fisher’s Exact tests, or t-test. Compliance with ECG submission was evaluated using 21 
one-way ANOVA. The primary outcome of time to AF diagnosis and relationships 22 
between baseline characteristics and AF outcome were evaluated using Cox regression. 23 
Major adverse outcomes were also compared between groups using Cox regression. 24 
Comparison of the distribution of questionnaire responses was made using the 25 
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Wilcoxon rank-sum test. All analyses were performed using SPSS version 22.0 (IBM 1 
Corp. Released 2013. IBM SPSS Statistics for Macintosh, Armonk, NY: IBM Corp). 2 
RESULTS 3 
Participants 4 
We invited 5846 individuals to participate (5726 identified via GP records, 120 in 5 
person during attendance at clinical research facility for other study-related visit). Of 6 
these, 3305 did not reply and 1269 declined participation. The 1272 volunteers were 7 
reviewed further by telephone/verbal screening, of whom 240 did not meet criteria for 8 
inclusion (24 with AF not identified on initial notes review, 22 taking warfarin, 4 with 9 
permanent pacemaker 127 with no internet access and 63 miscellaneous) and were not 10 
invited to attend for further screening. A further 28 of the 1032 who attended for a 11 
screening visit were excluded, 18 due to a new AF diagnosis on screening iECG ; 10 for 12 
other reasons (including inability to obtain interpretable iECG traces or to use the 13 
device properly [N=5], lack of access to the internet [N=2] or previously unidentified 14 
exclusion criteria [N=3]).  15 
 16 
We randomized 1004 participants, of whom 3 were excluded immediately after 17 
enrolment for protocol violations: one who was noted to have been in AF on their 18 
baseline iECG trace (missed at the time of screening) one with an uninterpretable iECG 19 
at baseline and one who was found to have had prior hemorrhagic stroke on further 20 
review of their medical notes (Figure 1). 21 
 22 
Age, sex and clinical characteristics of study participants were similar in iECG and RC 23 
groups (Table 1). All risk factors were well represented except for heart failure (N=14). 24 
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Baseline medication prescription was similar in both study groups (Supplement 2 1 
Table). All randomized participants were in sinus rhythm at baseline. 2 
 3 
We were able to access the NHS records of all patients to establish mortality and 4 
cardiovascular admissions during the study period. Three participants in the iECG arm 5 
withdrew (1 after completing 12 week and 2 after 12 and 32 week follow-up calls) and 6 
2 were lost to follow up (1 after participation in 12 week and 1 after 12 and 32 week 7 
follow-up). All other patients completing the study participated fully in all telephone 8 
interviews at 12, 32 and 52 week except for 1 follow-up call missed at 32 weeks by an 9 
iECG participant. All practices responded to our requests regarding whether or not AF 10 
had been diagnosed in their respective patients 11 
 12 
iECG recording and transmission 13 
The participants in the iECG arm recorded 60,440 ECGs over the 12-month follow-up 14 
period. 74% of participants completed the trial without missing a single week of ECG 15 
submission. Recommended twice-weekly ECGs were submitted successfully on average 16 
by the iECG participants in 39 of the 52 weeks and at least one weekly ECG was 17 
submitted in 48 out of the 52 weeks of the trial. Approximately 4 out of 5 of participants 18 
submitted at least 1 weekly iECG during ≥90% and at least 2 iECGs during ≥75% of the 19 
study weeks (Figure 2). Increasing participant age did not affect compliance; mean 20 
number of study weeks with iECG transmitted on 2 (or more) separate days was similar 21 
in those aged 65-75y, 75-79y and 80y+ ( 77%, 73% and 74% respectively, p = 0.143).  22 
Of the 76% of iECGs that were reported normal by the automated algorithm, none were 23 
finally confirmed to be AF; only 6 iECGs of the 21% reported as undetermined were 24 
finally confirmed to be AF; only 5% of the approximately 1% iECGs reported as AF by 25 
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the device were finally confirmed to be in AF and 2.2% of iECGs were reported as 1 
unreadable. 2 
 3 
Newly Diagnosed AF 4 
Nineteen patients in the iECG group were diagnosed with AF during the 12-month study 5 
period vs 5 in the RC arm (Hazard Ratio 3.9, 95%CI = 1.4-10.4, p = 0.007)(Figure 3). Ten 6 
iECG patients had a ventricular rate >100/min at the time of diagnosis and the other 9 7 
between 60-100/min. There were no significant differences in compliance between 8 
those diagnosed with AF (iECG group n = 19) and those not diagnosed with AF (mean 9 
study weeks with iECG submitted on 2 separate days in those diagnosed vs not 10 
diagnosed with AF=69% vs 76% respectively, one way ANOVA p = 0.11). 11 
The iECG patients diagnosed with AF had CHADS-VASc scores of 2(N=3), 3(N=5), 4(N=7, 12 
5(N=2) and 6(N=1); RC AF patients had CHADS-VASc scores of 2 (N=1), 3(N=2) and 13 
4(N=2). Twelve (63%) of the iECG patients diagnosed with AF had paroxysmal AF at the 14 
time of diagnosis and 7 (37%) were in persistent AF, compared with 0 (0%) and 5 15 
(100%) respectively in the RC arm.  16 
 17 
Eight (42%) of the iECG patients were asymptomatic at the time of diagnosis, with only 18 
4 (21%) experiencing palpitations and 7 (37%) aware of other symptoms. In the RC 19 
arm, two (40%) were diagnosed with AF during palpitations and the other 3 (60%) 20 
during other symptoms. 21 
 22 
Trends for the relationship between baseline variables and development of AF were as 23 
expected, although only age (>75), CHADS-VASc (≥4) and arterial disease were 24 
statistically significantly associated with an increased likelihood AF diagnosis (Table 2). 25 
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Including all variables in a regression model (excluding HF which was rare) only 1 
CHADS-VASc ≥4 remained a significant predictor of AF (adjusted hazard ratio=4.0, 95% 2 
CI 1.1 to 15.2, p = 0.04). Similar findings were noted when only significant variables 3 
were included in a single model (less susceptible to over-fitting given the relatively 4 
small event rate). The hazard ratio, and significance, for the difference between 5 
treatment groups also remained unchanged in a model adjusting for baseline variables 6 
(in any combination). For example, adjusting for CHADS-VASc ≥4, the hazard ratio 7 
between study groups was 3.9 (95% CI 1.5-10.4) p = 0.007. CHADS-VASc ≥4 also 8 
remained significant in the mutually adjusted model. Study arm (iECG) also remained 9 
significantly associated with an increased likelihood of AF diagnosis after adjustment 10 
for CHADS-VASc in a further model. 11 
 12 
Patients diagnosed with AF in the iECG arm were all treated promptly with 13 
anticoagulation (9 with warfarin and 10 with a non-coumadin OAC [NOAC]). In the RC 14 
arm, 3 were treated with warfarin, 1 with NOAC and 1 with clopidogrel. 15 
 16 
Clinical Events 17 
There were no significant differences in the number of serious adverse clinical events 18 
occurring in each arm. Although numerically fewer, there was no statistically significant 19 
difference in the numbers of strokes or TIAs (6 vs 10 in iECG and RC arms respectively, 20 
hazard ratio = 0.61, 95%CI = 0.22-1.69, p=0.34). Table 3, Supplement 3 Figure). There 21 
were no peripheral arterial embolic events. In the iECG arm, one participant suffered a 22 
hemorrhagic stroke (not previously found to be in AF/anticoagulated) and one suffered 23 
an ischemic stroke during a complicated post-operative course following aortic valve 24 
replacement surgery. The other 4 events in the iECG group were of undetermined 25 
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aetiology. In the RC arm, two of these events were embolic due to AF diagnosed 1 
following presentation with stroke, 6 stroke/TIA were of undetermined aetiology and 2 2 
were due to carotid disease. Thus 4 ischemic strokes or TIAs were due to an uncertain 3 
cause in the iECG group and 8 due to AF or uncertain cause in the RC group (hazard 4 
ratio = 0.51, 95%CI (0.15, 1.7) p = 0.27).  5 
We noted 2 clinically significant bleeds (both lower GI) in the iECG arm and 1 (ocular) in 6 
the RC arm. None of these bleeds occurred in patients who had been anticoagulated 7 
following AF diagnosis. There were no differences between the study groups in the 8 
incidence of all cause mortality or significant adverse clinical events due to other causes 9 
(Table 3). 10 
 11 
Participant Experience Surveys 12 
Participants’ experience (reported using a 1-10 visual analogue scale), showed small 13 
increases in the iECG arm in the reported awareness of the risk (mean score 6.8 vs 6.1, p 14 
= 0.001) but slightly less anxiety about the risk of heart rhythm abnormalities and 15 
stroke (mean score 2.2 vs 2.5, p = 0.003) as well as slightly lower reported likelihood of 16 
intending to visit their physician regarding concerns about their heart rhythm (mean 17 
score 7.1 vs 7.5, p = 0.04). Notably, RC participants reported a considerably greater 18 
preference to have been able to switch to the other study arm (mean score 1.9 vs 6.2, p 19 
< 0.0001). 20 
 21 
Participants in the iECG group were further asked about their experience using the 22 
AliveCor device during the study (measured on a 5 point Likert scale). The vast majority 23 
of iECG participants were “Not at all” or “slightly anxious”, “Not at all restricted” by, 24 
14 
 
“Extremely” or “Very” confident in using the device, “Extremely” or “Very” comfortable 1 
with the process of sharing clinical, iECG and personal information with the study team 2 
and were generally “Extremely” or “Very” satisfied with use of the device. (Figure 4) 3 
 4 
Health Economic Analysis 5 
The overall cost of the intervention was $204,830 (£156,837).  This consisted of device 6 
costs of $28,698 (£21,974), patient training costs of $3,750 (£2,871) and defective 7 
technology costs of $2,194 (£1,680). A total of 60,440 ECGs were recorded, which 8 
amounted to a cost of $116,823 (£89,451) in commercial ECG over-reads. The cost of 9 
ECG pathway co-ordination was $37,793 (£28,938) and 704 ECGs were identified as ‘AF’ 10 
by AliveCor, producing a cost of $7,972 (£6,104) for cardiologist over-read. In addition, 11 
74 review appointments were made; 44 were nurse reviews and 30 cardiologist 12 
reviews. Overall, 19 cases of AF were detected thus the intervention cost was $10,780 13 
(£8,255) per AF diagnosis. 14 
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DISCUSSION 1 
In this study we found that regular twice-weekly iECG recording and submission is 2 
logistically feasible over a 1 year period and highly acceptable to people over 65 with 3 
increased risk of AF and stroke. This approach results in an almost four-fold increase in 4 
the likelihood of a diagnosis of AF being made over the course of a year at a cost of 5 
$10,780 (£8,255) per additional AF diagnosis. The overall incidence of stroke+TIA was 6 
similar in both groups, however, this study was not statistically powered to detect a 7 
difference in clinical events in this population.  8 
 9 
Outcome of Screening Strategy 10 
To be worthwhile, screening tests should employ a low-risk, accurate methodology with 11 
acceptable cost effectiveness. The success of such a strategy depends on the 12 
incidence/prevalence of the condition in the screened population and the accuracy of 13 
the testing strategy. As age is the strongest predictor of AF,1  a screening cutoff ≥65y is 14 
recommended based on expert consensus, 30 as the clinical- and cost-effectiveness of 15 
different screening strategies remains to be confirmed in randomized control trials 16 
(RCT) powered to evaluate outcomes.21  17 
 18 
We found 19 (1.84%) of the 1033 individuals to be in AF at the time of screening, 19 
despite careful pre-assessment to identify and exclude those with known AF. This 20 
compares favourably with new AF diagnosis in an iECG screening study of patients ≥65y 21 
visiting community pharmacy (1.5%).31 These findings contrast with the 0.5%  22 
diagnosed with AF at initial ECG screening in a community study of 75-76 year old 23 
patients.19, 31 However, in that study, new AF was diagnosed in a further 218 patients 24 
(3.0% 95%CI 2.7-3.5%) during 2 weeks of  twice daily ECG recording.  25 
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 1 
Studies evaluating incidence of AF with continuous monitoring/implantable devices 2 
have shown that atrial “high rate events” (usually AF) are generally associated with 3 
strokes or systemic thromboembolism, although there is frequently temporal 4 
discordance noted between the “AF” and thromboembolic event suggesting other 5 
contributing risk factors in these individuals.21 The RATE registry shows that short (15-6 
20s) episodes of AF/AT were not associated with an increased risk of stroke in device 7 
patients, whereas prolonged episodes were independently associated as were episodes 8 
lasting over 5min in the MOde Selection Trial and at least 6 minutes in the ASSERT 9 
study.12, 32,14  In contrast, other studies have found that only device-detected AF 10 
duration of several hours was associated with increased risk,13, 33, 34 A pooled analysis of 11 
3 studies suggested at least an hour’s duration of device-detected AT/AF was the best 12 
predictor of risk.35 We found that 63% of newly diagnosed AF was paroxysmal vs 37% 13 
persistent/permanent in the iECG arm; we have not further subdivided the latter as 14 
accurate classification would have required longer term follow-up of their subsequent 15 
care and should not affect consideration of stroke risk and indication for 16 
anticoagulation. It is unclear how the risk associated with increasing duration of AF 17 
identified with an implantable device compares with the risk associated with 18 
asymptomatic PAF of uncertain frequency and duration diagnosed during 19 
routine/screening evaluation. Nonetheless, recurrent episodes of PAF are common and 20 
as CHADS-VASc scores were high in iECG patients (all ≥2; most ≥3), we made the 21 
decision to anticoagulate all patients identified with (P)AF according to ESC and local 22 
guidance.24, 30  23 
 24 
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We found that age, arterial disease and CHADS-VASc scores were associated with an 1 
increased likelihood of AF diagnosis, but only a CHADS-VASc score ≥4 independently 2 
predicted AF . In the STROKESTOP study increasing CHADS-VASc score increased the 3 
likelihood of AF diagnosis, as did heart failure, which was relatively underrepresented 4 
in our study.19   5 
 6 
iECG Device and Monitoring Strategy 7 
We used the AliveCor device to record and upload iECGs in this study. This handheld 8 
technology involves use of a pair of electrodes linked to a mobile device to provide a 9 
single-lead rhythm strip comparable to Lead 1 of standard ECG.  It employs an FDA-10 
cleared automatic algorithm with 98% sensitivity and 97% specificity reported for AF 11 
diagnosis.22 AliveCor technology is already widely used for remote detection of AF and 12 
common arrhythmias in routine clinical practice, having several attractive features 13 
including the quality of the trace, a validated AF reporting algorithm, remote access for 14 
clinicians over a secure server, and HIPAA compliance. However, other validated 15 
technologies are available, 36-40 suggesting a need for comparative studies evaluating 16 
their relative effectiveness and acceptability.  17 
 18 
Mondays and Wednesdays were selected for ECG recording and transmission. As the 19 
small study team was only routinely available Monday to Friday this approach would 20 
allow the study coordinator to review the ECG reports the following day and arrange 21 
clinical evaluation within 24-48 hours of an abnormal ECG being uploaded . This 22 
approach could be varied in routine practice according to size and availability of the 23 
clinical team. 24 
 25 
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Clinical Events 1 
There were no significant differences in the number of serious adverse clinical events 2 
occurring in each arm. Although numerically fewer, there was no statistically significant 3 
difference in the numbers of strokes or TIAs. Of note, two patients presenting with 4 
strokes in the RC arm were found to have asymptomatic AF, one diagnosed at the time 5 
of and one shortly after presentation with stroke, whereas none of these events in iECG 6 
patients were due to previously undetected/untreated AF. Indeed, numerically fewer 7 
ischemic stroke/TIA in iECG participants were of uncertain aetiology (N=4) than in the 8 
RC arm of which 8 were due to definite AF or uncertain aetiology, although not 9 
statistically significantly different. Up to 30% of strokes of undetermined aetiology may 10 
be a consequence of previously undetected/untreated AF, with incidence varying 11 
according to the population characteristics and monitoring strategy.41  It is therefore 12 
possible that 1 in 3 or 4 of these events in our higher-risk population could have been 13 
due to undetected AF. Thus, our findings raise the possibility that remote iECG 14 
monitoring may not only increase detection of AF, but could also reduce the incidence of 15 
ischaemic stroke. This would clearly require a large RCT, appropriately powered to 16 
evaluate major clinical outcomes. 17 
 18 
Health Economic Evaluation 19 
We found the cost per diagnosis of AF to be £8,255 ($10,750) according to current UK 20 
National Health Service tariffs. Further detailed health economic analyses will permit 21 
modelling of the potential cost effectiveness of this approach to stroke prevention in the 22 
community. This will require imputation of multiple detailed assumptions including the 23 
accuracy of the detection rate, the estimated net risk reduction in those identified and 24 
treated and the specific costs of the systems required to implement the ongoing ECG 25 
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surveillance programme, which are beyond the remit of this clinical manuscript. 1 
Previous studies have suggested that point of care screening for AF in over 65s in 2 
primary care, community pharmacy or at influenza immunization could be cost 3 
effective31, 42, 43  as could the 2 week, twice daily period of ECG recording  in the 4 
STROKESTOP study.19 Our preliminary health economic findings are aligned with the 5 
conclusions from these and other studies19, 31  including a systematic review with cost-6 
effectiveness analysis.44 These indicated that both systematic opportunistic screening 7 
and systematic population screening followed by NOAC therapy, when indicated, are 8 
likely to be cost-effective compared with no screening (current practice). The costs per 9 
AF diagnosis in our study (where the mean age was 72.6) are lower than the costs 10 
derived by the economic model, but given that the aim of the study was to assess the 11 
costs of identifying AF, we have not yet factored the management of such patients into 12 
the overall costs and the longer-term benefits. It is unlikely that the additional costs of 13 
NOAC therapy will inflate the costs to such a degree that it would not represent value 14 
for money. Indeed, given the proportion of iECG AF patients provided with NOAC in our 15 
study (53%), we estimate that this approach is likely to result in an incremental net 16 
benefit (based on a cost/QALY of $26,118 (£20,000) with an incremental cost-QALY 17 
ratio of <$13,058 (<£10,000). Evidence from screening study cost-effectiveness 18 
modelling and systematic review highlights that at ages lower than 65 years and over 19 
80 years, screening strategies are less cost-effective but nevertheless remain within 20 
acceptable limits.19, 31, 44 Nonetheless, the full morbidity and mortality benefits and 21 
consequent health economic outcome, including specifically the impact of variation in 22 
uptake and effectiveness of anticoagulation in practice, can only be realistically 23 
determined by prospective randomized controlled outcome trials. 24 
 25 
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Uptake of Anticoagulation 1 
All of the patients diagnosed with AF in the iECG arm were started promptly on 2 
anticoagulation (53% with NOAC). We did not routinely collect data on medication 3 
concordance, nor time in therapeutic range on warfarin, as that was outside the scope of 4 
this screening study. These issues will influence the clinical effectiveness of a screening 5 
programme and require evaluation in a prospective outcome study. 6 
 7 
Limitations 8 
Our study is the first randomized, prospective study to examine the effectiveness of 9 
longer-term intermittent ECG recording to diagnose AF in an at risk population. Patients 10 
who did not have access to the Internet or could not use the device were excluded from 11 
participation in the study, excluding those who could not comply with the monitoring 12 
protocol which likely include a proportion of those at the highest risk. This introduces a 13 
potential selection bias towards our findings being representative of this approach in 14 
the more independent, educated elderly who would likely still benefit considerably 15 
from lower AF-related stroke risk. Nonetheless, we were still able to recruit a large 16 
number of older patients who were no less compliant than the younger patients in our 17 
population. All study patients required internet access and documentation of 18 
proficiency with the device at screening, excluding additional bias between groups. The 19 
majority of iECG patients submitted traces on two occasions per week. Despite their 20 
generally very good concordance with the monitoring protocol and higher AF diagnosis 21 
rate, it is likely that asymptomatic paroxysmal AF has been missed in some participants, 22 
albeit unlikely that persistent/permanent AF was missed. Increasing the frequency of 23 
iECG acquisition should increase AF detection rate, but would increase logistical and 24 
financial demand on clinical services as well as further burden participants. Although 25 
21 
 
longer-term continuous external monitoring or use of implantable devices to identify 1 
incident AF would be expected to increase the capture of clinically relevant AF episodes, 2 
such approaches would not be without an adverse effect on patients in terms of 3 
convenience, discomfort, risk and acceptability. We were interested to note that 4 
participants were generally very satisfied with the AliveCor device and study protocol, 5 
with most finding it easy and acceptable to use, without increasing anxiety regarding 6 
their heart or likelihood of consulting with their physician. It was particularly 7 
noteworthy that RC participants expressed a far greater preference to have been 8 
allocated to the iECG arm. These findings provide reassurance that if such a programme 9 
is considered clinically and economically viable in the future, it will also be highly 10 
acceptable to the target population. 11 
 12 
Only the iECG patients were contacted and brought back for clinical review +/- further 13 
testing where clinically indicated by their iECG results. There was no specific instruction 14 
regarding how to manage RC patients and data on nature and frequency of these visits 15 
for comparison have not been formally evaluated. Although we did not undertake a full 16 
face to face clinical evaluation and chart review of all patients at the completion of the 17 
study, all patients underwent detailed questioning at 12, 32 and 52 weeks with specific 18 
reference to heart rhythm abnormalities and major clinical events with only one missed 19 
call accounting for those dying, withdrawing or being lost to follow-up. Furthermore, 20 
patients and practitioners tended to notify us at the time of most relevant clinical events 21 
during follow up, with deaths and cardiovascular admissions confirmed through the 22 
NHS Wales clinical IT system. Whilst it is possible that events were underreported 23 
because patients did not remember or chose not to report them, participants were on 24 
the whole very engaged with the study and happy to volunteer relevant clinical 25 
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information. It is possible that the closer contact between the study team and iECG 1 
participants would make it more likely that relevant events would have been missed in 2 
RC patients. 3 
 4 
We have not yet completed a full assessment of the diagnostic performance of the 5 
device and the reporting service. This is an extensive undertaking and beyond the scope 6 
of this manuscript. Our initial analysis of the diagnostics shows that a normal 7 
automated iECG report provides excellent negative predictive ability to exclude AF, but 8 
there appears to be a relatively high false positive rate in the small proportion of those 9 
reported as AF by the device, with these data and patients requiring careful review. A 10 
full, detailed evaluation of agreement between the automated alogorithm and 11 
overreading physiologist and cardiologist has not been completed and will be the 12 
subject of a further manuscript. Patients often submitted multiple ECGs when the 13 
automated report suggested AF or undetermined and clinical review with confirmatory 14 
testing required in several cases. These factors have been considered in the health 15 
economic evaluation.  16 
 17 
The study was not blinded, with ECG over reads, diagnosis of AF and determination of 18 
clinical outcomes undertaken by the senior physician investigators. Although ECG and 19 
clinical diagnoses were validated, an element of observer bias cannot be excluded. The 20 
study was conducted in a single centre, based in a UK University Hospital with the 21 
majority of participants of white European ethnicity and thus the findings may not be 22 
generalizable to different patient populations or healthcare systems. We could not be 23 
certain that patients were truly free from (paroxysmal) AF prior to enrolment, but we 24 
excluded anyone with a prior record of AF in their primary care record or reported a 25 
23 
 
prior diagnosis of AF as well as the 19 who were found to be in (asymptomatic) AF on 1 
their initial iECG (including one who was inappropriately randomised and excluded due 2 
to protocol violation). We excluded cardiac pacing subjects as we felt that identification 3 
of asymptomatic high atrial rate episodes during routine pacing checks could 4 
potentially bias the results of the study. We acknowledge that this could have been a 5 
useful control, but as the numbers would have been small, any question of diagnostic 6 
superiority of internal vs intermittent external monitoring could not be answered 7 
definitively in this study.  8 
The study data were analysed and reported independently and without involvement of 9 
the company. The investigators do not have any fiduciary involvement with the 10 
company. 11 
 12 
Summary and Conclusions 13 
Regular twice-weekly iECG screening is highly acceptable to people over 65 at increased 14 
risk of AF and stroke and results in an almost four-fold increase in the diagnosis of AF 15 
over the course of a year. This impact on AF detection and lower incidence of ischemic 16 
stroke/TIA due to AF or undetermined cause with this monitoring strategy, suggests a 17 
potential clinical benefit warranting further evaluation in a larger outcome trial.  18 
 19 
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Figure legends 1 
Figure 1: Recruitment of local participants over 65 years of age with CHADS-VASc≥2. 2 
 3 
Figure 2: Compliance in the iECG arm can be measured as the proportion of weeks in 4 
which a participant submits the recommended number of iECG. Here we show proportion 5 
of patients who submitted iECGs at least once per week (left panel) or at least twice per 6 
week vs the % of study weeks when this was achieved (fewer than 50%, 50-75%, 75-90%, 7 
or over 90% of the study weeks). 8 
 9 
Figure 3: Kaplan-Meier plot showing the estimated detection probabilities for AF in each 10 
arm of the study over the 52 weeks of the trial. Shaded areas represent 95% confidence 11 
regions. Log-rank p = 0.004 (Mantel-Cox). 12 
 13 
Figure 4: Pie charts showing iECF participant experience questionnaire responses to 14 
regarding use of AliveCor device in the study 15 
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Tables 1 
 iECG (N=500)  Routine Care (N=501) p-value 
Sex M/F  241/259 (48%/52%) 225/275 (45%/55%) 0.30 
Mean age (SD) 72.6 y (5.4)  72.6 y (5.4) 0.98 
Age 65-74 y 328 330 0.93 
Age >= 75 y* 172 171 0.93 
Heart Failure 5 (1%)  9 (2%)  0.28 
Hypertension 268 (54%)  272 (55%) 0.75 
Diabetes Mellitus 129 (26%) 140 (28%)  0.43 
Stroke or TIA 35 (7%)  28 (6%) 0.37 
Vascular Disease 71 (14%)  79 (16%)  0.50 
CHADS-VASc  (SD) 3.0 (1.0)  3.0 (1.0) 0.57 
 2 
Table 1: Baseline characteristics of study participants. TIA=transient ischaemic attack.  3 
*65 patients in the iECG and 56 in the RC arm were at least 80 years of age. 4 
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 1 
 Hazard Ratio (95% CI) p-value  
Gender M/F 1.9 (0.9, 4.5) 0.11 
Age >= 75  2.3 (1.0, 5.1) 0.04 
Hypertension 0.91 (0.6, 1.4) 0.68 
Diabetes Mellitus 1.1 (0.7, 1.6) 0.79 
Stroke or TIA 1.2 (0.6, 2.5) 0.64 
Arterial Disease 1.5 (1.0, 2.4) 0.05 
CHADS-VASc Score ≥4 2.3 (1.0, 5.1) 0.04 
 2 
Table 2: Baseline variables as predictors of AF. The table shows results from separate Cox 3 
regression models. When variables were combined in a multivariable model, only CHADS-4 
VASc score of ≥4 was independently associated with an increased risk of being diagnosed 5 
with AF.  6 
 7 
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Adverse event iECG (N)          RC (N) p-value 
Death 3 5 0.51 
Stroke/TIA/SE 6 10 0.34 
Clinically Significant Bleeds 2 1 0.56 
DVT/PE 3 1 0.31 
Other cardiovascular 8 13 0.27 
Respiratory 7 3 0.20 
Neurological 3 2 0.65 
Orthopaedic/Musculoskeletal/Fall 14 14 0.99 
Gastroenterological 10 10 0.99 
Renal / Urological 2 5 0.26 
Other 7 6 0.78 
 1 
Table 3: Adverse clinical events. Raw numbers of events in each arm of the study. 2 
Comparison between groups (p-values) were calculated using Cox regression. 3 
 4 
 5 
 6 
 7 
